Table 1

Distribution of demographic and clinical characteristics by ART regimen

	Total (N=1 23 002)		First-line regimen (N=1 17 260)		Second-line regimen (N=5742)
Characteristic	Median	IQR	Median	IQR	Median	IQR
Age at ART start, years (N=1 23 002)	33	28–39	33	28–39	33	28–39
Current age*, years (N=1 23 002)	38	32–45	38	32–45	41	36–47
Duration on ART, months (N=1 23 002)	64	31–105	62	30–103	107	75–131
CD4 cell count at start of ART (N=95 697)	200 cells/µL	101–337 cells/µL	205 cells/µL	106–342 cells/µL	116 cells/µL	44–204 cells/µL
Most recent CD4 cell count* (N=98 626)	336 cells/µL	188–522 cells/µL	337 cells/µL	190–523 cells/µL	318 cells/µL	154–516 cells/µL
Viral load (N=84 252)	124 copies/mL	45–124 copies/mL	124 copies/mL	44–124 copies/mL	124 copies/mL	49–231 copies/mL
<1000 copies/mL	124 copies/mL	40–124 copies/mL	124 copies/mL	40–124 copies/mL	124 copies/mL	39–124 copies/mL
≥1000 copies/mL	36 883 copies/mL	7090–1 55 883 copies/mL	37 900 copies/mL	7225–1 59 021 copies/mL	32 271 copies/mL	6110–1 40 000 copies/mL
Characteristic	Frequency	Percentage	Frequency	Percentage	Frequency	Percentage
Facility (N=1 23 002)
Charlotte Maxeke Hospital	11 545	9.39	10 309	8.79	1236	21.53
Hillbrow CHC	54 328	44.17	51 103	43.58	3225	56.17
Jeppe Clinic	14 765	12.00	14 647	12.49	118	2.06
Malvern Clinic	9621	7.82	9512	8.11	109	1.90
Rosettenville Clinic	8216	6.68	8138	6.94	78	1.36
South Rand Hospital	10 385	8.44	8138	8.33	613	10.68
Yeoville Clinic	14 142	11.50	13 779	11.75	363	6.32
Age at ART start, years (N=1 23 002)
<25	18 476	15.02	17 597	15.01	879	15.31
25–34	51 649	41.99	49 287	42.03	2362	41.14
35–49	45 932	37.34	43 749	37.31	2183	38.02
50+	6945	5.65	6627	5.65	318	5.54
Current age*, years (N=1 23 002)
<25	7875	6.40	7544	6.43	331	5.76
25–34	33 372	27.13	32 555	27.76	817	14.23
35–49	64 432	52.38	60 903	51.94	3529	61.46
50+	17 323	14.08	16 258	13.86	1065	18.55
Sex (N=1 23 000)
Female	79 226	64.41	75 752	64.60	3474	60.50
Male	43 774	35.59	41 506	35.40	2268	39.50
Total duration on ART, years (N=1 23 002)
<5	48 575	39.49	47 765	40.73	810	14.11
5–9	45 791	37.23	43 691	37.26	2100	36.57
≥10	28 636	23.28	25 804	22.01	2832	49.32
Baseline CD4 cell count at start of ART (N=95 697)
≤100 cells/µL	23 764	24.83	21 731	23.83	2033	45.00
101–200 cells/µL	24 190	25.28	22 873	25.09	1317	29.15
201–350 cells/µL	25 757	26.92	25 005	27.42	752	16.64
351–500 cells/µL	11 318	11.83	11 077	12.15	241	5.33
>500 cells/µL	10 668	11.15	10 493	11.51	175	3.87
Most recent CD4 cell count* (N=98 626)
≤100 cells/µL	12 432	12.61	11 595	12.40	837	16.39
101–200 cells/µL	14 248	14.45	13 454	14.39	794	15.55
201–350 cells/µL	24 988	25.34	23 845	25.50	1143	22.39
351–500 cells/µL	19 961	20.24	18 984	20.30	977	19.13
>500 cells/µL	26 997	27.37	25 642	27.42	1355	26.54
Viral load (N=84 252)
<1000 copies/mL	76 737	91.08	72 451	91.79	4286	80.61
≥1000 copies/mL	7515	8.92	6484	8.21	1031	19.39
DTG-based regimen (N=1 23 002)
DTG-based regimen	1479	1.20	1460	1.25	19	0.33
Without DTG	121 523	98.80	115 800	98.75	5723	99.67
Retention status (N=1 23 002)
Active in care	57 981	47.14	54 898	46.82	3083	53.69
Deceased	895	0.73	830	0.71	65	1.13
LTFU	39 195	31.87	37 588	32.06	1607	27.99
Transferred/moved out	24 931	20.27	23 944	20.42	987	17.19

*Current age=patient’s age when data were extracted for the analysis from TIER.Net; most recent CD4 cell count=most recent CD4 cell count available in the database.
ART, antiretroviral therapy; DTG, dolutegravir; LTFU, lost to follow-up; N, number.